Aptus Pharma Reports Strong Financial Growth and Proposes Bonus Issue

Revenue surged by 89.59% to ₹46.71 crore in FY 2025-26.
Profit After Tax (PAT) grew by 49.05% to ₹4.62 crore.

Reader Takeaway: Robust growth and strategic expansion offer positive outlook, but execution risk remains a watch point.

What just happened

Aptus Pharma has released its financial results for FY 2025-26, showcasing a significant increase in revenue and profitability. The company's turnover rose by 89.59% to ₹46.71 crore compared to ₹24.64 crore in the previous fiscal year. EBITDA saw a 57.73% jump to ₹7.50 crore, and Profit After Tax (PAT) increased by 49.05% to ₹4.62 crore.

In addition to strong financial performance, the Board of Directors has recommended a 3:2 bonus share issue, subject to shareholder approval. This means investors would receive 3 additional shares for every 2 shares held.

Why this matters

The substantial revenue and profit growth indicates Aptus Pharma's expanding market presence and operational efficiency. The proposed bonus issue is a direct reward to shareholders and reflects management's confidence in the company's sustained growth potential and financial health. Furthermore, the company is actively pursuing strategic expansions into new, high-potential segments like neuro-psychiatric care and life-saving injectables, alongside plans for vertical integration through manufacturing subsidiaries and export market development.

The backstory

Aptus Pharma has maintained a consistent growth trend over the past four fiscal years. Turnover has climbed from ₹13.90 crore in FY 2022-23 to ₹46.71 crore in FY 2025-26. PAT has also seen a significant improvement, rising from ₹0.19 crore in FY 2022-23 to ₹4.62 crore in FY 2025-26.

What changes now

With board approval for the bonus issue pending shareholder consent, the company aims to increase its equity base and potentially improve stock liquidity. The ongoing expansion strategies into new therapeutic divisions, a wholly-owned subsidiary for nutraceuticals and cosmeceuticals, and a focus on exports to Latin America, Africa, and Asia are expected to diversify revenue streams and enhance profit margins. The company continues to leverage an asset-light model with contract manufacturing.

Risks to watch

While the company's outlook appears positive, investors should note potential risks. Management has acknowledged that forward-looking statements carry inherent risks, and actual results could differ materially. The successful execution of new ventures, including the manufacturing and export subsidiaries, and acceptance of new product lines in competitive markets will be crucial for achieving projected growth.

Peer comparison

(No direct peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue Growth (FY25-26 vs FY24-25): +89.59%
• EBITDA Growth (FY25-26 vs FY24-25): +57.73%
• PAT Growth (FY25-26 vs FY24-25): +49.05%
• Revenue Growth (FY25-26 vs FY22-23): From ₹13.90 crore to ₹46.71 crore
• PAT Growth (FY25-26 vs FY22-23): From ₹0.19 crore to ₹4.62 crore

What to track next

Investors should closely monitor the shareholder approval process for the 3:2 bonus issue. Progress on the establishment and operationalization of the new manufacturing and export subsidiaries will be key indicators of future growth and margin expansion. Tracking the performance of the Aptus Mindcare and Aptus Orbit divisions, as well as the entry into the Life-Saving Injectables & ICU Care segment, will also be important.